Navigation Links
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Date:5/15/2012

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC System.

(Logo:  http://photos.prnewswire.com/prnh/20120514/SF06703LOGO)

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue (lung volume reduction), restore elastic recoil, and adjust lung compliance.  This treatment offers a minimally invasive alternative to lung volume reduction surgery to a broad range of emphysema patients. 

The RePneu LVRC has already undergone extensive clinical studies in Europe, with impressive results in over 250 treatments.  The majority of subjects who underwent RePneu LVRC treatment in PneumRx's European clinical trials experienced significant improvement in lung function, exercise capacity and quality of life at both 6 months and one year after treatment, with minimal risk.  74% of all clinical subjects maintained a clinically significant improvement in exercise capacity at 12 months post-treatment and 96% experienced significant improvement in quality of life.

Specifically, RePneu LVRC subjects experienced a mean improvement in Six-Minute Walk Test of 62 meters; a 12% increase in FEV1, a 10% decrease in Residual Volume  and a decrease of 12 points in the St. George's Respiratory Questionnaire, at 12 months.  The European clinical trial results were used to support PneumRx's CE Mark, and the RePneu LVRC System has been commercially available in Europe since 2010.

The RePneu LVRC has proven effective in patients with both heterogeneous and homogeneous disease, in both the upper and lower lobes, and it works independently of collateral ventilation.  The safety profile of the RePneu LVRC System is comparable to that of a simple bronchoscopy procedure, with the majority of adverse results occurring, and resolving, within 30 days of treatment.  Patients generally return home from the hospital the day after the treatment.

"We are thrilled to have IDE approval for the RePneu LVRC and are eager to bring this exciting technology to the United States," said Erin McGurk, PneumRx's President and CEO.  "It has been so gratifying to see the benefits the RePneu LVRC treatment has brought to emphysema patients in Europe and we are especially pleased to be able to bring these benefits to a greater number of patients suffering from this debilitating disease here in the United States.  We plan to treat over 300 subjects in our pivotal trial, and expect to start enrolling clinical subjects in the coming months.  We look forward to submitting the pivotal trial results in support of a PMA application to sell the RePneu LVRC System in the United States."

"The entire PneumRx team, in partnership with our accomplished team of Physician Advisors, has worked tirelessly to support the RePneu LVRC IDE application and design an appropriate clinical trial," stated Kara Andersen Reiter, Vice President of Regulatory Affairs at PneumRx.  "We are grateful to the FDA team who reviewed our IDE application and worked with us to bring our submission over the finish line."

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.

Website

www.pneumrx.com


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PneumRx, Inc. Raises $33 Million in Capital
2. PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
3. MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes
4. Flexpoint Receives Purchase Order for Medical Device Used in Procedure Performed Millions of Times Annually
5. Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
6. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
7. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
8. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
9. Alexza Receives Complete Response Letter for Adasuve™ NDA
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... 03, 2020 , ... In response to the COVID-19 pandemic ... classrooms across the United States, IntraLogic Solutions , a leading national school ... a non-contact, wall-mounted scanning thermometer that rapidly checks body temperatures. When a level ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... will host the Agilent Science and Technology Virtual Symposium 2020 (ASTVS 2020) ... Agilent will open a suite of Live webinars and Networking sessions, with a ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are ... (CDC), About 3% of breast cancers (about 7,500 women per year) and 10% of ... and BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put ... and look for ways to trim the fat from our monthly expenses and put more ... it’s also important that you have a financial safety net in place in case something ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang ... persons with autism and other developmental disabilities, as well as supporting staff in ... adolescents with autism, school consultation, and staff development. She joined the company in ...
(Date:8/28/2020)... ... 28, 2020 , ... Ernst & Young LLP (EY US) ... Of The Year® 2020 Florida Award finalist. Now in its 34th year, the ... growth and prosperity as they build and sustain successful businesses that transform our ...
(Date:8/28/2020)... ... August 28, 2020 , ... With ... set out to continue helping the specialty-diet community connect with great, gluten-free brands. ... get coupons, enter giveaways, chat with brands & watch over 50 educational classes... ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... that strongly suggest that obese individuals are at an increased risk of developing ... more likely to catch COVID-19; however, because the same organ systems that the ...
Breaking Medicine News(10 mins):